Media stories about Rewalk Robotics (NASDAQ:RWLK) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rewalk Robotics earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 45.3908776727032 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
Shares of RWLK stock remained flat at $$1.05 on Friday. 365,492 shares of the stock traded hands, compared to its average volume of 236,447. The company has a market cap of $32.17 million, a P/E ratio of -1.06 and a beta of 0.55. Rewalk Robotics has a 12-month low of $1.00 and a 12-month high of $3.20. The company has a quick ratio of 1.15, a current ratio of 1.47 and a debt-to-equity ratio of -5.23.
Rewalk Robotics (NASDAQ:RWLK) last announced its quarterly earnings data on Thursday, May 10th. The medical device company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. The firm had revenue of $1.58 million for the quarter, compared to the consensus estimate of $1.27 million. Rewalk Robotics had a negative net margin of 360.66% and a negative return on equity of 1,154.65%. equities analysts expect that Rewalk Robotics will post -0.7 earnings per share for the current year.
Several research firms have weighed in on RWLK. ValuEngine upgraded shares of Rewalk Robotics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Canaccord Genuity restated a “buy” rating and set a $2.00 price objective on shares of Rewalk Robotics in a research report on Monday, March 12th. Oppenheimer set a $3.00 price objective on shares of Rewalk Robotics and gave the company a “buy” rating in a research report on Wednesday, March 28th. Finally, Barclays restated a “sell” rating and set a $1.00 price objective on shares of Rewalk Robotics in a research report on Friday, March 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $2.58.
About Rewalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.